Unopposed production of granulocyte-macrophage colony-stimulating factor by tumors inhibits CD8+ T cell responses by dysregulating antigen-presenting cell maturation

Journal of Immunology

Volumn 162, Issue 10, 1999, Pages 5728-5737

  Bronte, Vincenzo ^a   Chappell, Dale B ^b   Apolloni, Elisa ^a   Cabrelle, Anna ^a   Wang, Michael ^b   Hwu, Patrick ^c   Restifo, Nicholas P ^a,c  

^a Dept of Oncol and Surg Sciences ^*  (United States)

^b HOWARD HUGHES MEDICAL INSTITUTE   (United States)

^c NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD11B ANTIGEN; CD8 ANTIGEN; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 4; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN PRESENTING CELL; ARTICLE; CANCER CELL CULTURE; CELL CONTACT; CELL MATURATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; DENDRITIC CELL; FEMALE; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; SUPPRESSOR CELL;

EID: 0033562982     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (62)

1. Overwijk, W. W., A. Tsung, K. R. Irvine, M. R. Parkhurst, T. J. Goletz, K. Tsung, M. W. Carroll, C. Liu, B. Moss, S. A. Rosenberg, and N. P. Restifo. 1998. gp100/pmel 17 is a murine tumor rejection antigen: induction of "self'-reactive, tumoricidal T cells using high-affinity, altered peptide ligand. J. Exp. Med. 188: 277.
2. + T lymphocytes. Proc. Natl. Acad. Sci. USA In press.
3. Rosenberg, S. A., J. C. Yang, D. J. Schwartzentruber, P. Hwu, F. M. Marincola, S. L. Topalian, N. P. Restifo, M. E. Dudley, S. L. Schwarz, P. J. Spiess, et al. 1998. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nat. Med. 4:321.
4. Pan, Z. K., G. Ikonomidis. A. Lazenby, D. Pardoll, and Y. Paterson. 1995. A recombinant Listeria monocytogenes vaccine expressing a model tumour antigen protects mice against lethal tumour cell challenge and causes regression of established tumours. Nat. Med. 1:471.
5. Dyall, R., W. B. Bowne, L. W. Weber, J. LeMaoult, P. Szabo, Y. Moroi, G. Piskun, J. J. Lewis, A. N. Houghton, and J. Nikolic-Zugic. 1998. Heteroclitic immunization induces tumor immunity. J. Exp. Med. 188:1553.
6. Pardoll, D. M. 1998. Cancer vaccines. Nat. Med. 4:525.
7. Restifo, N. P., D. R. Surman, H. Zheng, P. Palese, S. A. Rosenberg, and A. Garcia-Sastre. 1998. Transfectant influenza A viruses are effective recombinant immunogens in the treatment of experimental cancer. Virology 249:89.
8. Restifo, N. P. 1998. Cancer vaccines '98: a reductionistic approach. Mol. Med. Today 4:327.
9. Banchereau, J., and R. M. Steinman. 1998. Dendritic cells and the control of immunity. Nature 392:245.
10. Bronte, V., M. W. Carroll, T. J. Goletz, M. Wang, W. W. Overwijk, F. Marincola, S. A. Rosenberg, B. Moss, and N. P. Restifo. 1997. Antigen expression by dendritic cells correlates with the therapeutic effectiveness of a model recombinant poxvirus tumor vaccine. Proc. Natl. Acad. Sci. USA 94:3183.
11. + T cells after gene gun immunization. J. Exp. Med. 188:1075.
12. Ashley, D. M., B. Faiola, S. Nair, L. P. Hale, D. D. Bigner, and E. Gilboa. 1997. Bone marrow-generated dendritic cells pulsed with tumor extracts or tumor RNA induce antitumor immunity against central nervous system tumors. J. Exp. Med. 186:1177.
13. Oehler, L., O. Majdic, W. F Pickl, J. Stockl, E. Riedl, J. Drach, K. Rappersberger, K. Geissler, and W. Knapp. 1998. Neutrophil granulocyte-committed cells can be driven to acquire dendritic cell characteristics. J. Exp. Med. 187:1019.
14. Inaba, K., M. Inaba, M. Deguchi, K. Hagi, R. Yasumizu, S. Ikehara, S. Muramatsu, and R. M. Steinman. 1993. Granulocytes, macrophages, and dendritic cells arise from a common major histocompatibility complex class II-negative progenitor in mouse bone marrow. Proc. Natl. Acad. Sci. USA 90:3038.
15. Cella, M., A. Engering, V. Pinet, J. Pieters, and A. Lanzavecchia. 1997. Inflammatory stimuli induce accumulation of MHC class II complexes on dendritic cells. Nature 388:782.
16. Levitsky, H. I., J. Montgomery, M. Ahmadzadeh, K. Staveley-O'Carroll, F Guarnieri, D. L. Longo, and L. W. Kwak. 1996. Immunization with granulocyte-macrophage colony-stimulating factor-transduced, but not B7-1-transduced, lymphoma cells primes idiotype-specific T cells and generates potent systemic antitumor immunity. J. Immunol. 156:3858.
17. Thomas, M. C., T. F. Greten, D. M. Pardoll, and E. M. Jaffee. 1998. Enhanced tumor protection by granulocyte-macrophage colony-stimulating factor expression at the site of an allogeneic vaccine. Hum. Gene Ther. 9:835.
18. Dranoff, G., E. Jaffee, A. Lazenby, P. Golumbek, H. Levitsky, K. Brose, V. Jackson, H. Hamada, D. Pardoll, and R. C. Mulligan 1993. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc. Natl. Acad. Sci. USA 90:3539.
19. Albert, M. L, B. Sauter, and N. Bhardwaj. 1998. Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs. Nature 392:86.
20. Albert, M. L., S. A. Pearce, L. M. Francisco, B. Sauter, P. Roy, R. L. Silverstein, and N. Bhardwaj. 1998. Immature dendritic cells phagocytose apoptotic cells via αvβ5 and CD36, and cross-present antigens to cytotoxic T lymphocytes. J. Exp. Med. 188:1359.
21. Tsuchiya, Y., M. Igarashi, R. Suzuki, and K. Kumagai. 1988. Production of colony-stimulating factor by tumor cells and the factor-mediated induction of suppressor cells. J. Immunol. 141:699.
22. Takeda, K., K. Hatakeyama, Y. Tsuchiya, H. Rikiishi, and K. Kumagai. 1991. A correlation between GM-CSF gene expression and metastases in murine tumors. Int. J. Cancer 47:413.
23. Rokhlin, O. W., T. L. Griebling, N. V. Karassina, M. A. Raines, and M. B. Cohen. 1996. Human prostate carcinoma cell lines secrele GM-CSF and express GM-CSF-receptor on their cell surface. Anticancer Res. 16:557.
24. + cells. J. Immunol. 161:5313.
25. Bronte, V., K. Tsung, J. B. Rao, P. W. Chen, M. Wang, S. A. Rosenberg, and N. P. Restifo. 1995. IL-2 enhances the function of recombinant poxvirus-based vaccines in the treatment of established pulmonary metastases. J. Immunol. 154: 5282.
26. Wang, M., V. Bronte, P. W. Chen, L. Gritz, D. Panicali, S. A. Rosenberg, and N. P. Restifo. 1995. Active immunotherapy of cancer with a nonreplicating recombinant fowlpox virus encoding a model tumor-associated antigen. J. Immunol. 154:4685.
27. Gavin, M. A., M. J. Gilbert, S. R. Riddell, P. D. Greenberg, and M. J. Bevan. 1993. Alkali hydrolysis of recombinant proteins allows for the rapid identification of class I MHC-restricted CTL epitopes. J. Immunol. 151:3971.
28. Overwijk, W. W., D. R. Surman, K. Tsung, and N. P. Restifo. 1997. Identification of a Kb-restricted CTL epitope of β-galactosidase: potential use in development of immunization protocols for "self" antigens. Methods 12:117.
29. Stephens, N. D. 1996. GM-CSF secretion in primary cultures of normal and cancerous human renal cells. Kidney Int. 50:1044.
30. Trutmann, M. 1998. GM-CSF gene expression and protein production in human colorectal cancer cell lines and clinical tumor specimens. Int. J. Cancer. 77:378.
31. Pericle, F., R. A. Kirken, V. Bronte, G. Sconocchia, L. DaSilva, and D. M. Segal. 1997. Immunocompromised tumor-bearing mice show a selective loss of STAT5a/b expression in T and B lymphocytes. J. Immunol. 159:2580.
32. Jaffe, M. L., H. Arai, and G. J. Nabel. 1996. Mechanisms of tumor-induced immunosuppression: evidence for contact-dependent T cell suppression by monocytes. Mol. Med. 2:692.
33. Irvine, K. R., R. S. Chamberlain, E. P. Shulman, D. R. Surman, S. A. Rosenberg, and N. P. Restifo. 1997. Enhancing efficacy of recombinant anticancer vaccines with prime/boost regimens that use two different vectors. J. Natl. Cancer Inst. 89:1595.
34. Irvine, K. R., R. S. Chamberlain, E. P. Shulman, S. A. Rosenberg, and N. P. Restifo. 1997. Route of immunization and the therapeutic impact of recombinant anticancer vaccines. J. Natl. Cancer Inst. 89:390.
35. Jiang, W., W. J. Swiggard, C. Heufler, M. Peng, A. Mirza, R. M. Steinman, and M. C. Nussenzweig. 1995. The receptor DEC-205 expressed by dendritic cells and thymic epithelial cells is involved in antigen processing. Nature 375:151.
36. Kronin, V., K. Winkel, G. Suss, A. Kelso, W. Heath, J. Kirberg, H. von Boehmer, and K. Shortman. 1996. A subclass of dendritic cells regulates the response of naive CDS T cells by limiting their IL-2 production. J. Immunol. 157:3819.
37. Suss, G., and K. Shortman. 1996. A subclass of dendritic cells kills CD4 T cells via Fas/Fas-ligand-induced apoptosis. J. Exp. Med. 183:1789.
38. Steinman, R. M., and M. D. Witmer. 1978. Lymphoid dendritic cells are potent stimulators of the primary mixed leukocyte reaction in mice. Proc. Natl. Acad. Sci. USA 75:5132.
39. Witmer-Pack, M. D., W. Olivier, J. Valinsky, G. Schuler, and R. M. Steinman. 1987. Granulocyte/macrophage colony-stimulating factor is essential for the viability and function of cultured murine epidermal Langerhans cells. J. Exp. Med. 166:1484.
40. Hakem, R., A. Hakem, G. S. Duncan, J. T. Henderson, M. Woo, M. S. Soengas, A. Elia, J. L. de la Pompa, D. Kagi, W. Khoo, et al. 1998. Differential requirement for caspase 9 in apoptotic pathways in vivo. Cell 94:339.
41. Sarin, A., M. L. Wu, and P. A. Henkart. 1996. Different interleukin-1β converting enzyme (ICE) family protease requirements for the apoptotic death of T lymphocytes triggered by diverse stimuli. J. Exp. Med. 184:2445.
42. Reap, E. A., K. Roof, K. Maynor, M. Borrero, J. Booker, and P. L. Cohen. 1997. Radiation and stress-induced apoptosis: a role for Fas/Fas ligand interactions. Proc. Natl. Acad. Sci. USA 94:5750.
43. Chinnaiyan, A. M., K. O'Rourke, B. R. Lane, and V. M. Dixit. 1997. Interaction of CED-4 with CED-3 and CED-9: a molecular framework for cell death. Science 275:1122.
44. Bender, A., M. Albert, A. Reddy, M. Feldman, B. Sauter, G. Kaplan, W. Hellman, and N. Bhardwaj. 1998. The distinctive features of influenza virus infection of dendritic cells. Immunobiology 198:552.
45. Restifo, N. P., and S. A. Rosenberg. 1999. Developing recombinant and synthetic vaccines for the treatment of melanoma. Curr. Opin. Oncol. 11:50.
46. Maraskovsky, E., K. Brasel, M. Teepe, E. R. Roux, S. D. Lyman, K. Shortman, and H. J. McKenna. 1996. Dramatic increase in the numbers of functionally mature dendritic cells in Flt3 ligand-treated mice: multiple dendritic cell subpopulations identified. J. Exp. Med. 184:1953.
47. Vremec, D., G. J. Lieschke, A. R. Dunn, L. Robb, D. Metcalf, and K. Shortman. 1997. The influence of granulocyte/macrophage colony-stimulating factor on dendritic cell levels in mouse lymphoid organs. Eur. J. Immunol. 27:40.
48. dim, B7-2) induce alloantigen-specific hyporesponsiveness in murine T lymphocytes. Transplantation 60:1539.
49. -) prolong cardiac allograft survival in nonimmunosuppressed recipients. Transplantation 62:659.
50. Qin, Z., G. Noffz, M. Mohaupt, and T. Blankenstein. 1997. Interleukin-10 prevents dendritic cell accumulation and vaccination with granulocyte-macrophage colony-stimulating factor gene-modified tumor cells. J. Immunol. 159:770.
51. Dummer, W., J. C. Becker, A. Schwaaf, M. Leverkus, T. Moll, and E. B. Brocker. 1995. Elevated serum levels of interleukin-10 in patients with metastatic malignant melanoma. Melanoma Res. 5:67.
52. Chen, Q., V. Daniel, D. W. Maher, and P. Hersey. 1994. Production of 1L-10 by melanoma cells: examination of its role in immunosuppression mediated by melanoma. Int. J. Cancer 56:755.
53. Schuler, G., and R. M. Steinman. 1997. Dendritic cells as adjuvants for immunemediated resistance to tumors. J. Exp. Med. 186:1183.
54. Gabrilovich, D. I., H. L. Chen, K. R. Girgis, H. T. Cunningham, G. M. Meny, S. Nadaf, D. Kavanaugh, and D. P. Carbone. 1996. Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells. [Published erratum appears in 1996 Nat. Med. 2:1267.] Nat. Med. 2:1096.
55. Nicoletti, G. 1985. Colony-stimulating activity from the new metastatic TS/A cell line and its high-and low-metastatic clonal derivatives. Br. J. Cancer 52:215.
56. Giovarelli, M. 1995. Local release of IL-10 by transfected mouse mammary adenocarcinoma cells does not suppress but enhances antitumor reaction and elicits a strong cytotoxic lymphocyte and antibody-dependent immune memory. J. Immunol. 155:3112.
57. Restifo, N. P., F. Esquivel, Y. Kawakami, J. W. Yewdell, J. J. Mule, S. A. Rosenberg, and J. R. Bennink. 1993. Identification of human cancers deficient in antigen processing. J. Exp. Med. 177:265.
58. 2-mrcroglobulin in metastatic melanomas from five patients receiving immunotherapy. J. Natl. Cancer Inst. 88:100.
59. Chouaib, S., C. Asselin-Paturel, F. Mami-Chouaib, A. Caignard, and J. Y. Blay. 1997. The host-tumor immune conflict: from immunosuppression to resistance and destruction. Immunol. Today 18:493.
60. Chappell, D. B., and N. P. Restifo. 1998. T cell-tumor cell: a fatal interaction? Cancer Immunol. Immunother. 47:65.
61. Chappell, D. B., T. Z. Zaks, S. A. Rosenberg, and N. P. Restifo. 1999. Human melanoma cells do not express Fas (Apo-1/CD95) ligand. Cancer Res. 59:59.
62. Brandt, S. J. 1988. Effect of recombinant human granulocyte-macrophage colony-stimulating factor on hematopoietic reconstitution after high-dose chemotherapy and autologous bone marrow transplantation. N. Engl. J. Med. 318:869.